



Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 8/17/2016

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

Appendix B, Table 6. Characteristics of CCR5 Antagonist (Last updated March 27, 2012; last reviewed April 8, 2015)

Generic Name (Abbreviation)/ Trade Name	Formulation	Dosing Recommendations ^a	Serum Half-Life	Elimination/ Metabolic Pathway	Adverse Events ^b
Maraviroc (MVC) <i>Selzentry</i>	<ul style="list-style-type: none"> • 150 and 300 mg tablets 	<ul style="list-style-type: none"> • 150 mg BID when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r) • 300 mg BID when given with NRTIs, T20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers • 600 mg BID when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) • Take without regard to meals. 	14–18 hours	CYP3A4 substrate	<ul style="list-style-type: none"> • Abdominal pain • Cough • Dizziness • Musculoskeletal symptoms • Pyrexia • Rash • Upper respiratory tract infections • Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions • Orthostatic hypotension, especially in patients with severe renal insufficiency

^a For dosage adjustment in hepatic insufficiency, see [Appendix B, Table 7](#).

^b Also see [Table 14](#).

Key to Abbreviations: BID = twice daily; CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T20 = enfuvirtide; TPV/r = tipranavir/ritonavir